Harnessing the immune system for the treatment of non-small-cell lung cancer.
Explore this paper's citation graph
Summary
Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways, and these therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.
- Type
- review
- Published
- 2013-03-10
- Cited by
- 156
- References
- 50
- OpenAlex
- https://openalex.org/W2147415023
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19337858
Keywords
Medicine, Immunotherapy, Immune system, Ipilimumab, Immunology
References
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
- Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
- Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.
- Immunotherapy for advanced renal cell cancer.
- Lymphocyte subsets in pulmonary venous and arterial blood of lung cancer patients.
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
- Immune alterations and emerging immunotherapeutic approaches in lung cancer
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer
- Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
- Plasma transforming growth factor‐β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Lymphocyte subsets in lung cancer.
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
- Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
- TGFβ signalling: a complex web in cancer progression
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
- Epidermal growth factor-related peptides and their receptors in human malignancies.
Cited by
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
- PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
- Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
- New Approaches in Immunotherapy for the Treatment of Lung Cancer.
- Utilisation d'un anticorps monoclonal anti-Tn en immunothérapie des cancers
- Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment
- Current and future molecular profiling of cancer by next-generation sequencing.
- PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
- Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression
- Update on systemic therapy of advanced non-small-cell lung cancer
- Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase
- Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy
- Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer
- Objective measurement and clinical significance of TILs in non-small cell lung cancer.
- Actual status of therapeutic vaccination in non-small cell lung cancer
- Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
Related papers
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy
- New opportunities for nanoparticles in cancer immunotherapy
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- Drug Delivery Strategies Based on Nanotechnology for Cancer Immunotherapy
- Nanotechnology in the arena of cancer immunotherapy
- Nanotechnology Approaches to Improving Cancer Immunotherapy
- Immunotherapy as an Option for Cancer Treatment